RDYNYSEPharmaceutical PreparationsFiscal year ends March 31
DR REDDYS LABORATORIES LTD
Financials through fiscal 2025, year ended Mar 31, 2025
$13.08+0.01 (+0.08%)
Close on Oct 19, 2026
Dr Reddys Laboratories statistics
Financials through Mar 31, 2025, price-based ratios appear once a share price is available
Valuation
| Market Cap | ₹1.06T |
|---|---|
| Enterprise Value | ₹1.09T |
| PE Ratio | 18.67 |
| PS Ratio | 3.24 |
| PB Ratio | 3.17 |
| P/TBV Ratio | 4.70 |
| P/FCF Ratio | 55.80 |
| P/OCF Ratio | 22.75 |
Enterprise value
| EV / Sales | 3.35 |
|---|---|
| EV / EBITDA | 12.28 |
| EV / EBIT | 15.20 |
| EV / FCF | 57.70 |
Income (trailing twelve months)
| Revenue | ₹325.54B |
|---|---|
| Gross Profit | ₹190.43B |
| Operating Income | ₹71.84B |
| Pretax Income | ₹76.78B |
| Net Income | ₹56.54B |
| EBITDA | ₹88.90B |
| EPS (Diluted) | 67.78 INR |
Margins
| Gross Margin | 58.5% |
|---|---|
| Operating Margin | 22.1% |
| Pretax Margin | 23.6% |
| Profit Margin | 17.4% |
| EBITDA Margin | 27.3% |
| FCF Margin | 5.81% |
Returns
| Return on Equity (ROE) | 17.0% |
|---|---|
| Return on Assets (ROA) | 11.5% |
| Return on Invested Capital (ROIC) | 14.7% |
| Return on Capital Employed (ROCE) | 19.8% |
Growth
| Revenue Growth (YoY) | 16.6% |
|---|---|
| Net Income Growth (YoY) | 1.54% |
| EPS Growth (YoY) | 1.47% |
| FCF Growth (YoY) | -34.8% |
| Revenue Growth (3Y CAGR) | 14.9% |
| Revenue Growth (5Y CAGR) | 13.3% |
| EPS Growth (3Y CAGR) | 33.7% |
| EPS Growth (5Y CAGR) | 23.6% |
Balance sheet
| Cash & Short-Term Investments | ₹14.65B |
|---|---|
| Total Debt | ₹46.77B |
| Net Cash (Debt) | -₹32.11B |
| Net Cash Per Share | -38.47 INR |
| Equity (Book Value) | ₹333.39B |
| Book Value Per Share | 399.43 INR |
| Tangible Book Value | ₹224.78B |
| Working Capital | ₹119.72B |
Financial position
| Current Ratio | 1.92 |
|---|---|
| Quick Ratio | 0.81 |
| Debt / Equity | 0.14 |
| Debt / EBITDA | 0.53 |
| Debt / FCF | 2.47 |
| Net Debt / EBITDA | 0.36 |
| Interest Coverage | 25.40 |
Cash flow (trailing twelve months)
| Operating Cash Flow | ₹46.43B |
|---|---|
| Capital Expenditures | -₹27.50B |
| Free Cash Flow | ₹18.92B |
| FCF Per Share | 22.67 INR |
Efficiency
| Asset Turnover | 0.66 |
|---|---|
| Inventory Turnover | 1.90 |
Dividends and yields
| Earnings Yield | 5.35% |
|---|---|
| FCF Yield | 1.79% |
| Dividend Yield | 3.16% |
| Shareholder Yield | 3.16% |
| Dividend Per Share | 40.00 INR |
| Dividend Growth (YoY) | 0.00% |
| Years of Dividend Growth | 0 |
| Payout Ratio | 11.8% |
| FCF Payout Ratio | 35.2% |
Shares
| Shares Outstanding | 834,657,000 |
|---|---|
| Shares Change (YoY) | 0.08% |
| Float | 720,995,000 |
| Shares Held by Insiders | 13.6% |
| Shares Held by Institutions | 15.1% |
Taxes
| Income Tax | ₹19.54B |
|---|---|
| Effective Tax Rate | 25.4% |
Scores
| Graham Number | 780.48 INR |
|---|---|
| Graham Upside | -38.3% |
| Altman Z-Score | 6.40 |
| Piotroski F-Score | 2 |
| Beneish M-Score | -1.95 |
Calculated by StockData from Dr Reddys Laboratories's SEC filings. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.